Specialty
Aesthetics Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

Ocular Hypertension and Primary Open-Angle Glaucoma

By: L. Jay Katz, MD, Moderator; Jason Bacharach, MD; Yvonne M. Buys, MD; Louis B. Cantor, MD

This course has expired. You can still review the content but course credit is no longer available.

Supplement Credits: 1

This continuing medical education (CME) activity captures content from a roundtable discussion held in May 2016.
This certified CME activity is designed for glaucoma specialists and general ophthalmologists involved in the management of glaucoma and associated disorders.

Expiration Date: Monday, July 31, 2017
Release Date: July 2016

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Discuss the limitations of current treatment regimens from both mechanism of action and patient compliance.
  • Explain how novel therapeutics differ in their methods of action from commercially available topical medications
  • Evaluate the safety and efficacy of different treatment modalities for ocular hypertension and primary open-angle glaucoma
  • Assess the latest clinical trial data pertaining to new therapies
  • Discuss future developments and direction of therapeutics for managing glaucoma

Accreditation and Designation Statement

ACCREDITATION STATEMENT

Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Disclosures

L. Jay Katz, MD, moderator
Wills Eye Hospital
Philadelphia, Pennsylvania

Jason Bacharach, MD
North Bay Eye Associates
Sonoma, California

Yvonne M. Buys, MD
Toronto Western Hospital
Toronto, Canada

Louis B. Cantor, MD
Indiana University School of Medicine
Indianapolis, Indiana

It is the policy of Evolve Medical Education LLC that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve Medical Education LLC has full policies in place that will identify and resolve all conflict of interests prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

L. Jay Katz, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Aerie Pharmaceuticals; Aerpio Therapeutics; Alcon; Allergan; Glaukos Corporation; Inotek Pharmaceuticals; and Ocular Therapeutix. Grant/Research Support: Aerie Pharmaceuticals; Alcon; Allergan; Bausch & Lomb Incorporated; Glaukos Corporation; InnFocus; Inotek Pharmaceuticals; and Mati Therapeutics. Stock/Shareholder: Aerie Pharmaceuticals; Glaukos Corporation; and Mati Therapeutics.

Jason Bacharach, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Aerie Pharmaceuticals; Alcon; Allergan; Glaukos Corporation; and Sun Pharmaceutical Industries Ltd. Grant/Research Support: Aerie Pharmaceuticals; Alcon; Allergan; Bausch & Lomb Incorporated; and Glaukos Corporation. Stock/Shareholder: Glaukos Corporation.

Yvonne M. Buys, MD, has had no financial agreement or affiliations during the past year.

Louis B. Cantor, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Abbott Medical Optics; Allergan; Glaukos Corporation; Inotek Pharmaceuticals; Mati Therapeutics; and Ocular Therapeutix. Grant/Research Support: Alcon; Allergan; and Bausch & Lomb Incorporated.

Cheryl Cavanaugh, MS, director of operations, Evolve Medical Education LLC; Michelle Dalton, writer; and Melanie Lawler, PhD, reviewer, have no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC, Glaucoma Today, or Bausch & Lomb Incorporated.

Ocular Hypertension and Primary Open-Angle Glaucoma: An Update on Treatment Regimens

Jay Katz, MD, Moderator; Jason Bacharach, MD; Yvonne Buys, MD; and Louis Cantor, MD

BackNext